Viehl Carsten T, Frey Daniel M, Phommaly Chanpheng, Chen Tingting, Fleming Timothy P, Gillanders William E, Eberlein Timothy J, Goedegebuure Peter S
Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA.
Breast Cancer Res Treat. 2008 May;109(2):305-14. doi: 10.1007/s10549-007-9657-x. Epub 2007 Jul 26.
Mammaglobin-A (MGB) is a breast cancer-associated antigen that is an attractive target for immune intervention. MGB has been shown to induce a specific CD8 T cell response in breast cancer patients, but little is known about a possible MGB-specific CD4 T cell response.
Peripheral blood-derived CD4(+)CD25(-) T cells were stimulated in vitro with MGB-pulsed antigen-presenting cells (APC). The MGB and human leukocyte antigen (HLA) class II specificity of the CD4 T cell lines was confirmed by cytokine release following restimulation with autologous and allogenic APC pulsed with MGB from different sources. Candidate HLA class II-restricted epitopes were identified by computer algorithm and validated in cytokine release assays.
MGB-specific CD4 T cells were successfully generated in cultures from six of seven donors. Restimulation of MGB-specific CD4 T cells with MGB-pulsed APC induced significantly higher levels of interferon (IFN)-gamma release than APC pulsed with an irrelevant protein (P = 0.0004). Cultures from five of seven donors showed a pure Th1 type response as evidenced by the absence of interleukin (IL)-4. MGB-specific CD4 T cells recognized both recombinant and naturally processed MGB presented by APC. This recognition was HLA class II-restricted, as HLA-DR mismatched APC were not recognized. MGB-specific CD4 T cells from three of four donors recognized MGB-derived, HLA class II-restricted peptides pulsed onto APC.
We have successfully generated MGB-specific CD4 T cell cultures and identified candidate MGB HLA class II epitopes. These studies should facilitate study of the CD4 T cell response to MGB, and the development and monitoring of vaccine strategies targeting this unique antigen.
乳腺珠蛋白-A(MGB)是一种与乳腺癌相关的抗原,是免疫干预的一个有吸引力的靶点。已证明MGB可在乳腺癌患者中诱导特异性CD8 T细胞反应,但对于可能的MGB特异性CD4 T细胞反应知之甚少。
用MGB脉冲处理的抗原呈递细胞(APC)在体外刺激外周血来源的CD4(+)CD25(-) T细胞。通过用来自不同来源的MGB脉冲处理的自体和异体APC再次刺激后细胞因子的释放,确认CD4 T细胞系的MGB和人类白细胞抗原(HLA)II类特异性。通过计算机算法鉴定候选的HLA II类限制性表位,并在细胞因子释放试验中进行验证。
在7名供体中的6名供体的培养物中成功产生了MGB特异性CD4 T细胞。用MGB脉冲处理的APC再次刺激MGB特异性CD4 T细胞,诱导的干扰素(IFN)-γ释放水平明显高于用无关蛋白脉冲处理的APC(P = 0.0004)。7名供体中的5名供体的培养物显示出纯Th1型反应,白细胞介素(IL)-4的缺乏证明了这一点。MGB特异性CD4 T细胞识别APC呈递的重组和天然加工的MGB。这种识别受HLA II类限制,因为HLA-DR不匹配的APC未被识别。4名供体中的3名供体的MGB特异性CD4 T细胞识别脉冲到APC上的MGB衍生的、HLA II类限制性肽。
我们成功地产生了MGB特异性CD4 T细胞培养物,并鉴定了候选的MGB HLA II类表位。这些研究应有助于研究CD4 T细胞对MGB的反应,以及针对这种独特抗原的疫苗策略的开发和监测。